CD274 and cancer: Not surprisingly, immunomodulatory agents, such as those that block either the PD‐1/PD‐L1 or CTLA4 pathways, have been extensively investigated as cancer therapies,2, 4, 5 including ipilimumab for melanoma to supplement surgery, radiotherapy, and chemotherapy.6